Arcus Biosciences Ownership | Who Owns Arcus Biosciences?

Overview Forecast RevenueFinancials Chart Transcripts

Arcus Biosciences Ownership Summary

Arcus Biosciences is owned by 93.49% institutional investors, 27.06% insiders. Gilead sciences is the largest institutional shareholder, holding 29.62% of RCUS shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 3.79% of its assets in Arcus Biosciences shares.

RCUS Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Arcus Biosciences	93.49%	27.06%	-20.55%
Sector	Healthcare Stocks	42.54%	10.83%	46.63%
Industry	Biotech Stocks	45.22%	10.75%	44.04%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Gilead sciences	31.42M	29.62%	$427.38M
Blackrock	9.76M	11.33%	$148.69M
Blackrock funding, inc. /de	11.81M	11.13%	$160.63M
Vanguard group	6.63M	6.25%	$90.16M
Point72 asset management	4.33M	4.08%	$58.92M
Woodline partners lp	3.77M	3.55%	$51.27M
Suvretta capital management	3.69M	3.48%	$50.17M
State street	3.39M	3.20%	$46.17M
Siren	2.91M	2.74%	$39.60M
Fmr	2.30M	2.16%	$31.23M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Invus financial advisors	1.61M	27.51%	$24.55M
Gilead sciences	31.42M	23.86%	$427.38M
Sectoral asset management	368.07K	3.09%	$5.01M
Dafna capital management	627.63K	2.11%	$8.54M
Siren	2.91M	1.55%	$39.60M
Decheng capital	547.61K	1.30%	$7.45M
Boxer capital	1.60M	1.28%	$24.40M
Suvretta capital management	3.69M	1.28%	$50.17M
Parkman healthcare partners	652.68K	0.93%	$8.88M
Sofinnova investments	1.22M	0.91%	$16.62M

Top Buyers

Holder	Shares	% Assets	Change
Siren	2.91M	1.55%	1.30M
Millennium management	924.37K	0.01%	679.27K
Fisher asset management	729.15K	0.00%	640.99K
Decheng capital	547.61K	1.30%	387.61K
Candriam s.c.a.	378.44K	0.03%	378.44K

Top Sellers

Holder	Shares	% Assets	Change
Point72 asset management	4.33M	0.10%	-1.63M
Braidwell lp	-	-	-802.10K
Readystate asset management lp	-	-	-351.36K
Integral health asset management	-	-	-300.00K
Fmr	2.30M	0.00%	-277.27K

New Positions

Holder	Shares	% Assets	Change	Value
Candriam s.c.a.	378.44K	0.03%	378.44K	$5.15M
Abrdn	331.67K	0.01%	331.67K	$4.42M
Vestal point capital, lp	250.00K	0.15%	250.00K	$3.40M
Arrowstreet capital, limited partnership	239.42K	0.00%	239.42K	$3.26M
Axa investment managers	232.67K	0.01%	232.67K	$3.16M

Sold Out

Holder	Change
Dinuzzo private wealth	-1.00
Sjs investment consulting	-5.00
Jfs wealth advisors	-7.00
Mendota financial group	-7.00
Capital performance advisors llp	-10.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2025	191	4.37%	99,188,061	2.60%	93	1.13%	96	-4.95%	52	6.12%
Jun 30, 2025	189	-	99,642,989	2.55%	93	0.96%	105	-17.32%	51	70.00%
Mar 31, 2025	187	-3.11%	97,113,724	15.75%	98	1.17%	126	44.83%	30	-55.22%
Dec 31, 2024	119	-37.70%	59,398,024	11.54%	64	1.91%	52	-40.91%	38	-46.48%
Sep 30, 2024	190	-4.52%	53,251,839	2.50%	58	1.79%	89	-16.82%	70	16.67%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
iShares Core S&P Small-Cap ETF	4.03M	3.79%	-
Vanguard Total Stock Mkt Idx Inv	2.11M	1.98%	-46.72K
iShares Russell 2000 ETF	1.66M	1.56%	-
Vanguard US Total Market Shares ETF	1.62M	1.53%	-
SPDR® S&P Biotech ETF	1.20M	1.13%	2.69K
Fidelity Select Biotechnology	1.19M	1.12%	-18.20K
Fidelity Select Health Care	949.76K	0.90%	-
CT (Lux) American Smaller Com 9U USD	906.88K	0.86%	55.03K
Fidelity Select Pharmaceuticals Port	853.52K	0.80%	-
BNP Paribas US Small Cap ClassicC	790.40K	0.74%	2.05K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Dec 04, 2025	Jaen Juan C.	President	Sell	$2.05M
Nov 26, 2025	Azoy Alexander	Chief Accounting Officer	Sell	$49.40K
Nov 26, 2025	Goeltz II Robert C.	Chief Financial Officer	Sell	$125.00K
Nov 17, 2025	Jaen Juan C.	President	Sell	$162.31K
Nov 18, 2025	Jaen Juan C.	President	Sell	$99.74K

Insider Transactions Trends

Date	Buy	Sell
2025 Q4	-	15
2025 Q3	-	2
2025 Q2	-	-
2025 Q1	3	-
2024 Q4	-	2

RCUS Ownership FAQ

Who Owns Arcus Biosciences?

Arcus Biosciences shareholders are primarily institutional investors at 93.49%, followed by 27.06% insiders and -20.55% retail investors. The average institutional ownership in Arcus Biosciences's industry, Biotech Stocks , is 45.22%, which Arcus Biosciences exceeds.

Who owns the most shares of Arcus Biosciences?

Arcus Biosciences’s largest shareholders are Gilead sciences (31.42M shares, 29.62%), Blackrock (9.76M shares, 11.33%), and Blackrock funding, inc. /de (11.81M shares, 11.13%). Together, they hold 52.08% of Arcus Biosciences’s total shares outstanding.

Does Blackrock own Arcus Biosciences?

Yes, BlackRock owns 11.33% of Arcus Biosciences, totaling 9.76M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 148.69M$. In the last quarter, BlackRock decreased its holdings by -137K shares, a -1.39% change.

Who is Arcus Biosciences’s biggest shareholder by percentage of total assets invested?

Invus financial advisors is Arcus Biosciences’s biggest shareholder by percentage of total assets invested, with 27.51% of its assets in 1.61M Arcus Biosciences shares, valued at 24.55M$.

Who is the top mutual fund holder of Arcus Biosciences shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Arcus Biosciences shares, with 3.79% of its total shares outstanding invested in 4.03M Arcus Biosciences shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools